Business
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, December 4th at 4:00 PM ETOCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Closing Bell Series on Thursday, December 4, 2025 at 4:00 PM ET. As part of the event, Equels will participate in a moderated “fireside” chat that will
About this update from Aim Immunotech Inc.
[{"type":"image","alt":"AIM ImmunoTech Inc.","displaySize":"","headline":null,"caption":"AIM ImmunoTech Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ExfZBbISk6KxGeFYkBNhew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd","width":300,"height":160}},"lazy":false},{"type":"text","content":"Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, December 4th at 4:00 PM ET","length":118,"tagName":"p"},{"type":"text","content":"OCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Closing Bell Series on Thursday, December 4, 2025 at 4:00 PM ET.","length":300,"tagName":"p"},{"type":"text","content":"As part of the event, Equels will participate in a moderated “fireside” chat that will focus on AIM’s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing DURIPANC clinical trial in collaboration with AstraZeneca combining Ampligen and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer. Equels will also discuss the importance of a completed Phase 2 clinical trial performed in collaboration with Merck Sharp & Dohme LLC (“Merck”), which found that the combination therapy of Ampligen and Merck’s Keytruda (pembrolizumab) was well-tolerated and demonstrated clinical benefit in the treatment of advanced recurrent ovarian cancer. An abstract detailing the trial was recently presented at the 40th Annual SITC Meeting.","length":844,"tagName":"p"},{"type":"text","content":"Prior to the event, interested parties may submit questions in advance by emailing [email protected]. Equels will answer as many questions as possible in the time allowed.","length":167,"tagName":"p"},{"type":"text","content":"A live video webcast of the fireside chat will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will become available two hours following the liv...